For research use only. Not for therapeutic Use.
Opipramol (Ensidon) is an atypical tricyclic antidepressant (TCA). Opipramol acts primarily as a sigma (σ) receptor agonist and can potently interact with sigma recognition sites with a Ki value of 50 nM. Opipramol can be used for the research of generalized anxiety disorder (GAD)[1][2].
Opipramol can potently interact with sigma recognition sites with a Ki value of 50 nM[1].
Opipramol inhibit the uptake of [3H] DA in crude synaptosomal preparations with an IC50 value of 5.5 μM[1].
Opipramol (i.p.; 5-50 mg/kg) increases dopamine release in vivo[2].
| Catalog Number | R007501 |
| CAS Number | 315-72-0 |
| Synonyms | 2-[4-(3-benzo[b][1]benzazepin-11-ylpropyl)piperazin-1-yl]ethanol |
| Molecular Formula | C23H29N3O |
| Purity | ≥95% |
| InChI | InChI=1S/C23H29N3O/c27-19-18-25-16-14-24(15-17-25)12-5-13-26-22-8-3-1-6-20(22)10-11-21-7-2-4-9-23(21)26/h1-4,6-11,27H,5,12-19H2 |
| InChIKey | YNZFUWZUGRBMHL-UHFFFAOYSA-N |
| SMILES | C1CN(CCN1CCCN2C3=CC=CC=C3C=CC4=CC=CC=C42)CCO |
| Reference | [1]. H J Möller, et al. Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol. 2001 Feb;21(1):59-65. [2]. T S Rao, et al. Neurochemical characterization of dopaminergic effects of opipramol, a potent sigma receptor ligand, in vivo. Neuropharmacology. 1990 Dec;29(12):1191-7. |
